Dose-Effect Relationships of 166Ho Radioembolization in Colorectal Cancer
- PMID: 32591491
- DOI: 10.2967/jnumed.120.243832
Dose-Effect Relationships of 166Ho Radioembolization in Colorectal Cancer
Abstract
Radioembolization is a treatment option for colorectal cancer (CRC) patients with inoperable, chemorefractory hepatic metastases. Personalized treatment requires established dose thresholds. Hence, the aim of this study was to explore the relationship between dose and effect (i.e., response and toxicity) in CRC patients treated with 166Ho radioembolization. Methods: CRC patients treated in the HEPAR II and SIM studies were analyzed. Absorbed doses were estimated using the activity distribution on posttreatment 166Ho SPECT/CT. Metabolic response was assessed using the change in total-lesion glycolysis on 18F-FDG PET/CT between baseline and 3-mo follow-up. Toxicity between treatment and 3 mo was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5, and its relationship with parenchyma-absorbed dose was assessed using linear models. The relationship between tumor-absorbed dose and patient- and tumor-level response was analyzed using linear mixed models. Using a threshold of 100% sensitivity for response, the threshold for a minimal mean tumor-absorbed dose was determined and its impact on survival was assessed. Results: Forty patients were included. The median parenchyma-absorbed dose was 37 Gy (range, 12-55 Gy). New CTCAE grade 3 or higher clinical and laboratory toxicity was present in 8 and 7 patients, respectively. For any clinical toxicity (highest grade per patient), the mean difference in parenchymal dose (Gy) per step increase in CTCAE grade category was 5.75 (95% CI, 1.18-10.32). On a patient level, metabolic response was as follows: complete response, n = 1; partial response, n = 11; stable disease, n = 17; and progressive disease, n = 8. The mean tumor-absorbed dose was 84% higher in patients with complete or partial response than in patients with progressive disease (95% CI, 20%-180%). Survival for patients with a mean tumor-absorbed dose of more than 90 Gy was significantly better than for patients with a mean tumor-absorbed dose of less than 90 Gy (hazard ratio, 0.16; 95% CI, 0.06-0.511). Conclusion: A significant dose-response relationship in CRC patients treated with 166Ho radioembolization was established, and a positive association between toxicity and parenchymal dose was found. For future patients, it is advocated to use a 166Ho scout dose to select patients and yo personalize the administered activity, targeting a mean tumor-absorbed dose of more than 90 Gy and a parenchymal dose of less than 55 Gy.
Keywords: dosimetry; holmium; radioembolization.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2114-2123. doi: 10.1007/s00259-024-06645-6. Epub 2024 Feb 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38369678 Free PMC article.
-
First Evidence for a Dose-Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study.J Nucl Med. 2020 Apr;61(4):608-612. doi: 10.2967/jnumed.119.232751. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601696 Clinical Trial.
-
(⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24819055 Clinical Trial.
-
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.Semin Nucl Med. 2019 May;49(3):237-243. doi: 10.1053/j.semnuclmed.2019.01.008. Epub 2019 Feb 1. Semin Nucl Med. 2019. PMID: 30954190 Review.
-
Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21. Cardiovasc Intervent Radiol. 2022. PMID: 35729423 Free PMC article. Review.
Cited by
-
Gamma camera imaging characteristics of 166Ho and 99mTc used in Selective Internal Radiation Therapy.EJNMMI Phys. 2024 Apr 6;11(1):35. doi: 10.1186/s40658-024-00633-3. EJNMMI Phys. 2024. PMID: 38581559 Free PMC article.
-
Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2114-2123. doi: 10.1007/s00259-024-06645-6. Epub 2024 Feb 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38369678 Free PMC article.
-
Intraprocedural C-arm dual-phase cone-beam enhancement patterns correlate with tumor absorbed dose after radioembolization.Med Phys. 2024 Apr;51(4):3045-3052. doi: 10.1002/mp.16882. Epub 2023 Dec 8. Med Phys. 2024. PMID: 38064591
-
Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.Cancers (Basel). 2023 Sep 29;15(19):4791. doi: 10.3390/cancers15194791. Cancers (Basel). 2023. PMID: 37835485 Free PMC article.
-
Automatic healthy liver segmentation for holmium-166 radioembolization dosimetry.EJNMMI Res. 2023 Jul 15;13(1):68. doi: 10.1186/s13550-023-00996-1. EJNMMI Res. 2023. PMID: 37453996 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical